The performance of liver stiffness measurement (LSM) to monitor the changes in the severity of liver fibrosis in chronic hepatitis B (CHB) patients on antiviral treatment is uncertain.
Methods
We prospectively studied CHB patients undergoing paired liver biopsy and transient elastography before and at week 48 of antiviral treatment. Based on our previously reported LSM algorithm, advanced liver fibrosis (F3–4) could be excluded or confirmed at >90% confidence.
Results
A total of 71 CHB patients were studied. The median alanine aminotransferase (ALT) level decreased from 99I U/l to 33I U/l, and the median LSM decreased from 8.8 kPa to 6.6 kPa, respectively, from baseline to week 48. Overall, 17 and 11 patients had regression and progression of histological fibrosis, respectively. Areas under the receiver operating characteristics curves of the LSM algorithm at baseline and week 48 for advanced fibrosis were 0.80 (95% confidence interval [CI] 0.69– 0.90) and 0.78 (95% CI 0.64–0.92), respectively. The sensitivity of LSM algorithm to exclude advanced fibrosis was 100% at baseline and 75% at week 48. The specif-city of the LSM algorithm to diagnose advanced fibrosis was 84% at baseline and 91% at week 48. Overall, 11/28 (39%) patients with LSM that decreased by >30%, 28/41 (68%) of patients with LSM that changed within 30% and 1/2 (50%) patients with LSM that increased by >30% had decreased, unchanged and increased histological fibrosis stages, respectively.
Conclusions
LSM could predict advanced fibrosis during antiviral therapy according to the ALT-based algorithm. Decrease in absolute LSM value, which could be related to ALT normalization, was unreliable to indicate regression of liver fibrosis.
References
1.
ChanH.L.Y., SungJ.J.Y.Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis2006; 26: 153–161.
2.
LiawY.F., LeungN., KaoJ.H.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int2008; 2: 263–283.
3.
European Association for the Study of the Liver.EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol2009; 50: 227–242.
4.
LokA.S., McMahonB.J.Chronic hepatitis B. Hepatology2007; 45: 507–539.
5.
ChanH.L.Y., LeungN.W.Y., HuiA.Y.A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med2005; 142: 240–250.
6.
ChanH.L.Y., WongG.L.H., WongV.W.S.A review of the natural history of chronic hepatitis B in the era of transient elastography. Antivir Ther2009; 14: 489–499.
7.
WongV.W.S., WongG.L.H., ChimA.M.L.Surrogate end points and long-term outcome in patients with chronic hepatitis B. Clin Gastroenterol Hepatol2009; 7: 1113–1120.
8.
BravoA.A., ShethS.G., ChopraS.Liver biopsy. N Engl J Med2001; 344: 495–500.
GuhaI.N., RosenbergW.M.Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities. Clin Liver Dis2008; 12: 883–900.
11.
PoynardT., ZoulimF., RatziuV.Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol2005; 100: 1970–1980.
12.
FraquelliM., RigamontiC., CasazzaG.Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut2007; 56: 968–973.
13.
TalwalkarJ.A., KurtzD.M., SchoenleberS.J.Ultrasound-based treatment transient elastography for the detection of hepatic fibrosis: systemic review and meta-analysis. Clin Gastroenterol Hepatol2007; 5: 1214–1220.
14.
MarcellinP., ZiolM., BedossaP.Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int2009; 29: 242–247.
15.
WongG.L.H., WongV.W.S., ChoiP.C.L.Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin Gastroenterol Hepatol2008; 6: 1027–1035.
16.
ChanH.L.Y., WongG.L.H., ChoiP.C.L.Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat2009; 16: 36–44.
17.
WongG.L.H., WongV.W.S., ChoiP.C.L.Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut2009; 58: 111–117.
18.
WongG.L.H., WongV.W.S., ChoiP.C.L.Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. Clin Gastroenterol Hepatol2009; 7: 227–233.
19.
WongG.L.H., WongV.W.S., ChoiP.C.L.Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography. Am J Gastroenterol2008; 103: 3071–3081.
20.
WongV.W.S., VergniolJ., WongG.L.H.Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology2010; 51: 454–462.
21.
BedossaP., PoynardT.An algorithm for grading of activity in chronic hepatitis C. Hepatology1996; 24: 289–293.
22.
DeLongE.R., DeLongD.M., Clarke-PearsonD.L.Comparing the areas under two or more correlated receiver operating characteristic curves: a non-parametric approach. Biometrics1988; 44: 837–845.
23.
CocoB., OliveriF., MainaA.M.Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat2007; 14: 360–369.
24.
WongG.L.H., WongV.W.S., ChoiP.C.L.Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol2009; 24: 1002–1007.
25.
WongG.L.H., WongV.W.S., ChoiP.C.L.Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther2010; 31: 1095–1103.
26.
BedossaP., DargèreD., ParadiseV.Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology2003; 38: 1449–1457.
